Abstract Library

#4372 CVM-005: A multicentre, single-arm, phase IIa study of CVM-1118, a novel oral anti-vasculogenic mimicry (VM) agent, in patients with treatment-refractory advanced neuroendocrine tumours (NET)

Introduction: NETs are highly vascularised tumours and a viable target for anti-VM therapies. CVM-1118 is an anti-tumour agent with multiple MOAs, including disruption of VM networks and induction of apoptosis via targeting mitochondrial TRAP1 protein.

Conference:

Presenting Author: Yen C

Authors: Yen C, Chen M, Chen Y, Bai L, Chen J,

Keywords: CVM-1118, GEP-NET, anti-vasculogenic mimicry,

#2117 Neuroendocrine Tumors: An Australian Experience

Introduction: Neuroendocrine tumours (NETs) in Australia are rare, but are rising in incidence.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Ashoka Menon V, Reeders J, George M,

Keywords: retrospective, incidence, low to intermediate, neuroendocrine, australia,

#1179 A Phase II Study of Axitinib in Advanced Carcinoid Tumors: Preliminary Results

Introduction: NETs are highly vascularized neoplasms overexpressing VEGF as well as VEGFR. Axitinib is a TKI with selective picomolar potency against VEGFR-1, -2 and -3

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Cives M, Strosberg J, Campos T, Weber T, Nickerson M,

Keywords: axitinib, anti-angiogenesis, VEGFR,

#871 Success with Lutetium-177 DOTATATE Therapy in Cushing’s Syndrome Caused by Functional Pancreatic Neuroendocrine Tumor (pNET) with Ectopic Adrenocorticotropic Hormone (ACTH) Secretion Refractory to Concomitant Everolimus, Pasireotide and Metyrapone

Introduction: We report a case of a 59-year-old female presenting with florid ACTH-dependent Cushing’s syndrome complicated by pulmonary cryptococcal infection.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Chan B, Wyld D, Burge M, Cuneo R, Macfarlane D,

Keywords: pancreatic, neuroendocrine, tumor, ACTH, everolimus, pasireotide, lutetium,